Ali Adnan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ali Adnan has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Anders Högmo
Department of Oto‐Rhino‐Laryngology, Head and Neck Surgery Karolinska University Hospital Stockholm Sweden
2 shared publicationsErik Holmberg
Regional Cancer Center Western Sweden Sahlgrenska University Hospital Gothenburg Sweden
2 shared publicationsGöran Laurell
Department of Surgical Sciences, Section of Otorhinolaryngology and Head and Neck Surgery Uppsala University Uppsala Sweden
2 shared publicationsHelena Sjödin
Theme Cancer, HHLH Karolinska University Hospital Stockholm Sweden
2 shared publicationsIsak Notstam
Department of Clinical Sciences/ENT Umeå University Umeå Sweden
2 shared publicationsJohan Reizenstein
Department of Oncology Örebro University Hospital and Örebro University Örebro Sweden
2 shared publications
Latest Publications
- 24 September 2021
- Published by Wiley in Head & Neck
- Vol. 43 (12) , 3843-3856
A national study of health‐related quality of life in patients with cancer of the base of the tongue compared to the general population and to patients with tonsillar carcinoma
Background: This exploratory, registry‐based, cross‐sectional study aimed to evaluate patients' health‐related quality of life (HRQOL) in a subsite of oropharyngeal cancer: cancer of the base of the tongue (CBT).Methods: CBT patients, treated with curative intent, completed the EORTC QLQ‐C30 and QLQ‐H&N35 questionnaires 15 months after diagnosis. The HRQOL of CBT patients was compared to reference scores from the general population and to that of tonsillar carcinoma patients.Results: The 190 CBT patients scored significantly worse than members of the general population on most scales. CBT patients with human papilloma virus (HPV)‐positive tumors had significantly better HRQOL on 8 of 28 scales than HPV‐negative patients. Compared to 405 tonsillar carcinoma patients, CBT patients had significantly worse HRQOL on 8 of the 28 scales, the majority local head and neck related problems.Conclusion: One year after treatment, CBT patients' HRQOL was significantly worse in many areas compared to that of the general population and slightly worse than that of tonsillar carcinoma patients.
- 24 September 2021
- Published by Wiley in Head & Neck
- Vol. 43 (12) , 3843-3856
A national study of health‐related quality of life in patients with cancer of the base of the tongue compared to the general population and to patients with tonsillar carcinoma
Background: This exploratory, registry‐based, cross‐sectional study aimed to evaluate patients' health‐related quality of life (HRQOL) in a subsite of oropharyngeal cancer: cancer of the base of the tongue (CBT).Methods: CBT patients, treated with curative intent, completed the EORTC QLQ‐C30 and QLQ‐H&N35 questionnaires 15 months after diagnosis. The HRQOL of CBT patients was compared to reference scores from the general population and to that of tonsillar carcinoma patients.Results: The 190 CBT patients scored significantly worse than members of the general population on most scales. CBT patients with human papilloma virus (HPV)‐positive tumors had significantly better HRQOL on 8 of 28 scales than HPV‐negative patients. Compared to 405 tonsillar carcinoma patients, CBT patients had significantly worse HRQOL on 8 of the 28 scales, the majority local head and neck related problems.Conclusion: One year after treatment, CBT patients' HRQOL was significantly worse in many areas compared to that of the general population and slightly worse than that of tonsillar carcinoma patients.
- 10 February 2020
- Published by Wiley in Head & Neck
- Vol. 42 (5) , 860-872
Health‐related quality of life among tonsillar carcinoma patients in Sweden in relation to treatment and comparison with quality of life among the population
Background: The health‐related quality of life (HRQOL) of tonsillar carcinoma survivors was explored to investigate any HRQOL differences associated with tumor stage and treatment. The survivors' HRQOL was also compared to reference scores from the population.Methods: In this exploratory cross‐sectional study patients were invited 15 months after their diagnosis and asked to answer two quality of life questionnaires (EORTC QLQ‐ C30, EORTC QLQ‐ HN35), 405 participated.Results: HRQOL was associated with gender, with males scoring better than females on a few scales. Patients' HRQOL was more associated with treatment than tumor stage. Patients' HRQOL was worse than that in an age‐ and sex‐matched reference group from the normal population, the largest differences were found for problems with dry mouth followed by problems with sticky saliva, senses, swallowing and appetite loss.Conclusions: The tonsillar carcinoma patients had a worse HRQOL compared to the general population one year after treatment.
- 10 February 2020
- Published by Wiley in Head & Neck
- Vol. 42 (5) , 860-872
Health‐related quality of life among tonsillar carcinoma patients in Sweden in relation to treatment and comparison with quality of life among the population
Background: The health‐related quality of life (HRQOL) of tonsillar carcinoma survivors was explored to investigate any HRQOL differences associated with tumor stage and treatment. The survivors' HRQOL was also compared to reference scores from the population.Methods: In this exploratory cross‐sectional study patients were invited 15 months after their diagnosis and asked to answer two quality of life questionnaires (EORTC QLQ‐ C30, EORTC QLQ‐ HN35), 405 participated.Results: HRQOL was associated with gender, with males scoring better than females on a few scales. Patients' HRQOL was more associated with treatment than tumor stage. Patients' HRQOL was worse than that in an age‐ and sex‐matched reference group from the normal population, the largest differences were found for problems with dry mouth followed by problems with sticky saliva, senses, swallowing and appetite loss.Conclusions: The tonsillar carcinoma patients had a worse HRQOL compared to the general population one year after treatment.